baber/WOPTO huggingface dataset:
Patent CA-2390027-A1 (CA)
Inventor: MATTEJAT ARNO
IPC: H01M8/241
Filed: 2000-10-25
Abstract: When a fuel cell installation (41) is switched off, there is danger that residual oxygen remains in the fuel cells of the fuel cell installation (41) . Said residual oxygen results in undesired oxidations that considerably limit  the output and life-time of the fuel cell installation (41). The aim of the invention is therefore to make sure that enough hydrogen remains in the fuel  cells to bring the entire oxygen within the fuel cells to an electrochemical  reaction when the fuel cell installation is switched off. To this end, the invention provides a fuel cell installation (41) in which the anode gas chamber (7b, 51) adjoining the anodes (3a, 23a, 44a) of the fuel cells is at  least twice as big as the cathode gas chamber (7b, 51b) adjoining the cathod es (3b, 23b, 44b) of the fuel cells.
Patent CA-2391503-A1 (CA)
Inventor: PELTEKIAN ARDEM M
IPC: A47F10/06
Filed: 2002-06-25
Abstract: A method and layout for loading food and beverages onto a plurality of trays. The method includes, for each tray in the plurality of trays, performing tray-loading method that includes the steps of selecting a tray from the plurality of trays; and loading the tray with food and beverages, to form an individual, customized tray. Each step in the tray loading method is performed at a different station in a plurality of stations. A path of travel extends alongside the plurality of stations. The first step in the tray-loading method is executed at a starting point in the plurality of stations. The path of travel includes a starting point adjoining the first station. The last step in the tray-loading method is executed at a last station in the plurality of stations. The path of travel includes an end point adjoining the last station. The end point and the starting point in the path of travel are adjacent such that an operator can quickly move from performing the last step of the tray-loading method on a tray at the last station to perform in the first step of the tray-loading method on the next tray at the first station.
Patent CA-2391802-A1 (CA)
Inventor: SIRINYAN KIRKOR
IPC: A01N25/30
Filed: 2000-12-05
Abstract: La présente invention concerne l'utilisation de polysiloxanes contenant au moins un groupe ammonium quaternaire, comme adjuvants, dans des formulations de principes actifs larvicides et/ou ovicides, ainsi que des produits contenant a) un principe actif larvicide et/ou ovicide, b) un dérivé polysiloxane comportant au moins un groupe ammonium quaternaire par molécule, et, éventuellement, d'autres adjuvants et porteurs.
Patent CA-2393558-A1 (CA)
Inventor: THORESEN KJELL
IPC: G11B33/04
Filed: 2000-11-15
Abstract: A cover for storing and sending compact discs is described, which cover includes an upper part (7) and a lower part (1), which upper part (7) and lower part (1) can be swivelled relative to each other, and one of the parts (1, 7) is provided with a portion (2) for placement of the compact disc, means (3) of retaining the compact disc, and means (6, 8) of attaching the parts (1, 7) to each other in a separable manner, where the lower part (1) and the upper part (7) are hinged to each other and can be swivelled through an angle of 360~ in parallel relative to each other.
Patent CA-2394165-A1 (CA)
Inventor: HEIL WOLFGANG
IPC: A61K31/565
Filed: 2001-01-18
Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6.beta., 7.beta.;  15.beta.; 16.beta.-dimethylene-3-oxo-17.alpha.-preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.
Patent CA-2394579-A1 (CA)
Inventor: DIB MICHEL
IPC: A61K31/425
Filed: 2000-11-28
Abstract: La présente invention concerne l'utilisation de l'association d'une ergoline choisie parmi la nicergoline et le lumilysergol et de riluzole ou un de ses sels pharmaceutiquement acceptables dans la prévention et/ou le traitement des maladies motoneuronales.
Patent CA-2394880-A1 (CA)
Inventor: FOXWELL BRIAN
IPC: A61K38/095
Filed: 2000-12-22
Abstract: L'invention concerne l'activation de la réponse par des inhibiteurs de NF-.kappa.B, l'induction d'une réponse anergique par des inhibiteurs de NF-.kappa.B, et l'inhibition et l'activation de la réponse immunitaire par administration d'un activateur ou d'un inhibiteur de NF-.kappa.B. Des exemples d'inhibiteurs de NF-.kappa.B comprennent I.kappa.B.alpha., PSI, une séquence nucléotidique codant pour I.kappa.B.alpha., un acide nucléique anti-sens codant pour une séquence NF-.kappa.B, tel que Rel B, et des anticorps anti-NF-.kappa.B. Des exemples d'inducteurs de NF-.kappa.B comprennent NIK, MEKK, IKK2, TFRRF2 et Rel B. L'invention concerne également des vecteurs codant pour des inducteurs et pour des inhibiteurs de NF-.kappa.B, par exemple, des vecteurs adénoviraux.
Patent CA-2401311-A1 (CA)
Inventor: WELLMAN RONALD ALAN
IPC: B29D29/00
Filed: 2002-09-05
Abstract: A method and apparatus for manufacturing endless reinforced belts is disclosed.   The method comprising the steps of laying up on a flat build table at least one sheet of curable material and at least one sheet of reinforcement material forming a carcass, curing a central portion of the carcass, and then splicing and curing the uncured ends of the carcass to form the endless lugged track. The manufacturing system has three cells: a building cell, a flat cure press cell, and a splice cure press cell. Each cell is operated in series.
Patent CA-2401692-A1 (CA)
Inventor: DE LIMA CASTRO NETTO EDUARDO
IPC: G09F3/03
Filed: 2000-04-03
Abstract: The invention refers to a fastening-type security seal comprising a sealing body (1) with an internal tooth within the tunnel (2) and an elongated fastening part (8) possessing a series of sealing formations (11) throughout its length. The tip (13) of the fastening part (8) can be passed through the tunnel (2), so that the sealing formations (11) successively engage with an internal tooth (2b) in the tunnel, when the thus formed loop is tightened. An identification tag (3) is an integral part of the sealing body (1). With a view to eliminating the need to use a cutting instrument to remove the seal, without detracting from the physical resistance of the fastening part in the longitudinal direction, and also recucing the amount of plastic used in manufacturing the device, the tag (3) features a weakening line (15) that extends from the first edge (4) to the second edge (7) of the tag, dividing the tag into first region (17) on one side of the line (15) and second region on the other side of the line (15). The sealing body (1) is integrated with the first region (17) of the tab (3); the fastening part (8) is integrated with and extends from the second region (18) of the tag (3). And the tearing means is situated on the tag (3), adjacent to one of the ends of the weakening line, which enables one to tear the tag, thus separating the first region (17) from the second region (18).
Patent CA-2407554-A1 (CA)
Inventor: HEMSTOCK CHRISTOPHER A
IPC: B01D21/00
Filed: 2002-10-10
Abstract: A desanding vessel is connected to a fluid stream containing entrained particulates flowing from a wellhead. The vessel comprises an upper freeboard volume wherein the fluid velocity drops and particulates fall from suspension. Preferably the fluid stream is introduced offset upwardly from an axis of a horizontally-oriented cylindrical vessel, released particulates falling to accumulate in a lower belly portion. The freeboard volume is maintained using a depending flow barrier spaced from the fluid inlet and adjacent the vessel's outlet. A cleanout enables periodic removal of accumulations.
Patent CA-2409576-A1 (CA)
Inventor: ROQUES FRANCOIS
IPC: C03C8/08
Filed: 2001-06-25
Abstract: The present invention provides a composition for use in forming an enamel cover coat from which baked-on foods can be removed without the need for pyrolysis or highly alkaline cleaners. The enamel cover coat preferably exhibits no chipping or other surface defects subsequent to a 2.0 mm Plum Jam Test and an acid resistance of A or better according to ISO 2722. The composition according to the invention includes a glass component including at least a first glass frit comprising a low SiO2 glass frit. Preferably, the glass component includes a blend of the first glass frit and at least a second glass frit. Preferably, the first glass frit includes by weight from about 30%  to about 45% P2O5, from about 20% to about 40% Al2O3, from about 15% to about 35% Li2O + Na2O + K2O, up to about 15% B2O3, up to about 15% MgO + CaO + SrO +  BaO + ZnO, up to about 10% TiO2 + ZrO2, and up to about 10% SiO2.
Patent CA-2409657-A1 (CA)
Title: Heat transfer apparatus for sample containing well plates
Inventor: JONES CHRISTOPHER L
IPC: F28D20/00
Filed: 2002-02-22
Abstract: A thermal transfer comb includes numerous upwardly extending pins received in spaces around and between the sample containing wells of a well plate. Peltier effect modules are in contact with a base panel of the thermal transfer comb to apply heat to or remove heat from the comb. A heat sink and fan transfer heat from or to the modules.
Patent CA-2410766-A1 (CA)
Title: Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
Inventor: NJOROGE F GEORGE
IPC: A61P31/14
Filed: 2001-07-19
Abstract: The present invention discloses novel imidazolidinones which have HCV protea se inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
Patent CA-2411186-A1 (CA)
Inventor: ARRUDA VALDER R
IPC: A61K48/00
Filed: 2002-11-05
Abstract: Liver-directed gene transfer can induce immunological tolerance to a polypeptide associated with the expression of a therapeutic nucleic acid Hepatic expression of a transgene induces tolerance to the expression product of the transgene, or to post-translational product related to transgene expression, thereby ameliorating or eliminating the immune responses associated with gene therapy and protein replacement, respectively, independent of the genetic background of the subject.
Patent CA-2412283-A1 (CA)
Title: Double knit fabric with holes therethrough and a two color laminated effect fabric
Inventor: VIGEANT SYLVAIN
IPC: D04B1/10
Filed: 2002-11-20
Abstract: This double knit fabric which may be used for sports garments or uniforms, namely sweaters and stockings, may include a repeating pattern of predetermined courses containing wales of consecutive selected groups of tuck and welt stitches to form holes in and throughout the knitted fabric. The pattern may be repeated to provide a fabric with a considerable number of holes aligned in a predetermined geometrical arrangement and a two different colored laminated effect.
Patent CA-2413252-A1 (CA)
Inventor: OHYAMA TADASHI
IPC: A61K38/08
Filed: 2001-06-25
Abstract: Preventives or remedies for acute heart failure, chronic heart failure at th e flare stage or heart failure at the transitional stage into chronic heart failure, characterized by containing as the active ingredient D-alanyl-3- (naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysine ami de and/or salts thereof.
Patent CA-2417680-A1 (CA)
Title: Two-stage reconnect system and method
Inventor: DANG CUONG TU
IPC: H04L12/56
Filed: 2003-01-30
Abstract: Methods and systems for re-routing a connection through an explicitly routed network. The methods involve initially re-routing the connection to a reduced constraint connection through the network; establishing a fully constrained path through the network; subsequently re-routing the connection to the fully constrained connection through the network.
Patent CA-2418650-A1 (CA)
Title: Lens design to enhance vision quality
Inventor: YE MING
IPC: G02C7/04
Filed: 2001-08-16
Abstract: A contact lens includes a central zone and a peripheral zone. The central zo ne extends radially from a center to a central intermediate edge and has a radi us corresponding to a radius of a contracted pupil of a user when subjected to a high ambient light condition. The central zone also has a constant first refractive power across the central zone. The peripheral zone extends radial ly from the central intermediate edge to an outer edge and has a radius corresponding to a dilated pupil of the user. The peripheral zone has a refractive power that is equal to the first refractive power at the intermediate edge and that increases radially to a second refractive power, different from the first refractive power, at the outer edge. The contact le ns also includes a non-optical zone that extends radially from the outer edge t o an outermost radius corresponding to a radius of a user's cornea.
Patent CA-2418904-A1 (CA)
Inventor: BONHOMME MIREILLE MARGUERITE J
IPC: C07D498/04
Filed: 2001-08-07
Abstract: L'invention concerne l'utilisation d'un antagoniste de récepteurs 5-HT¿4? dans la fabrication d'un médicament pour prévenir ou traiter un remodelage auriculaire chez un mammifère. De préférence, l'antagoniste est du N-[(1?-n¿butyl-4-pipéridinyl) méthyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne aussi l'utilisation de SB 207266 ou d'un sel pharmaceutiquement acceptable de celui-ci dans la fabrication d'un médicament destiné à traiter ou à prévenir la fibrillation auriculaire chez un mammifère, par l'administration au mammifère d'une dose journalière, par voie orale ou parentérale, d'environ 0,2 mg à 1,0 mg de SB 207266 ou d'un sel de ce composé par kg de poids corporel total (mesuré comme base libre). L'invention concerne aussi l'utilisation de SB 207266 ou d'un sel pharmaceutiquement acceptable de ce composé dans la prévention ou le traitement d'arythmie auriculaire chez un mammifère, par l'administration de SB 207266 ou d'un sel pharmaceutiquement acceptable de ce composé, le premier jour à une dose initiale équivalant à environ 1,2 à environ 2,0 fois la dose d'entretien journalière ; suivie par l'administration, les jours suivants, de SB 207266 ou d'un sel pharmaceutiquement acceptable de ce composé à la dose d'entretien journalière.
Patent CA-2419429-A1 (CA)
Inventor: CHU CHIH-CHANG
IPC: A61K47/48
Filed: 2001-08-30
Abstract: L'invention concerne des copolyester amides élastomères, des copolyester uréthannes élastomères et des procédés permettant de produire ceux-ci. Les polymères décrits sont dérivés d'acides .alpha.-amino et possèdent des propriétés physiques, chimiques et de biodégradation adéquates. Ces polymères sont utiles en tant que véhicules de médicaments ou d'autres substances bioactives. Ces polymères peuvent être liés et/ou mélangés avec un ou plusieurs médicaments.
Patent CA-2420094-A1 (CA)
Title: Multi-layer absorbent wound dressing
Inventor: BURTON SCOTT A
IPC: B32B7/02
Filed: 2001-08-28
Abstract: A multi-layer wound dressing comprising at least two absorbent layers, and materials for forming absorbent layers are provided. The absorbent layers have different absorbencies, with the layer closest to the wound having a lower absorbency than the layer furthest from the wound. The wound dressing typically contains additional non-absorbing layers, such as a backing film and wound-facing film. The dressing provides absorbency of wound exudates while preventing the absorbent material from entering the wound. In specific implementations the dressing is substantially transparent prior to application to a wound, as well as after application to the wound when body fluids have been absorbed.
Patent CA-2421194-A1 (CA)
Title: Fabric conditioning composition comprising a hardened triethanaolamine-based fabric softening compound
Inventor: PARSONS JOHN STUART
IPC: C11D1/62
Filed: 2001-08-24
Abstract: An aqueous fabric conditioning composition comprises (a) 7.5 to 60% by weight of a cationic fabric softening compound of a quaternary ammonium softening compound, the compound having one or more hydrocarbyl chains formed from parent fatty acyl compounds or fatty acids having an iodine value of between 0 and 20, (b) 0.01% - 1.5% by weight of a nonionic surfactant viscosity modifier and (c) optionally up to 1.4% by weight of a fatty alcohol wherein the combination of (b) and (c) is no more than 1.5% by weight of the composition and the composition comprises particles having a mean diameter of from 0.3 to 7 microns, measured using a Malvern Mastersizer. The fabric conditioning compositions of the present invention have an improved long term storage stability. The fabric conditioning compositions of the present invention further have an improved fabric softening performance over fabric conditioning compositions that contain unsaturated or partially unsatutated compounds. The fabric conditioning compositions of the present invention also have less base odour than fabric conditioning compositions comprising unsaturated softening compounds.
Patent CA-2421321-A1 (CA)
Inventor: HILL JONATHAN
IPC: A61K38/00
Filed: 2003-03-07
Abstract: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid Arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of Rheumatoid Arthritis.
Patent CA-2422416-A1 (CA)
Inventor: JOWETT FREDERICK HAIGH
IPC: G06F17/30
Filed: 2001-09-13
Abstract: A system configured to distribute data in a user specified manner, comprising:  means for receiving requests for data from at least one client; and means for configuring data to be in a form compatible with a platform upon which the client is supported, and for distributing data to said client, said data configured in accordance with said user specification. The present invention provides a method and system for providing continuity of data/information/services to a user alongside portability with respect to the supporting platform.
Patent CA-2423942-A1 (CA)
Inventor: GERHARDT BRENDA
IPC: C12N1/21
Filed: 2001-09-24
Abstract: La présente invention concerne de nouvelles séquences polynucléotidiques et polypeptidiques qu'on peut utiliser dans des applications thérapeutiques, diagnostiques et pharmacogénomiques.
Patent CA-2430493-A1 (CA)
Inventor: SIMBLETT GERRY
IPC: H04M7/00
Filed: 2001-12-17
Abstract: A service management system is provided which allows call distribution using a call plan to be executed using several service execution platforms from different manufacturers, which may be associated with different network types.  Associated methods are also provided.
Patent CA-2433012-A1 (CA)
Title: Apparatus and method for embolizing an aneurysm with magnetically-controllable substance
Inventor: WALLACE MICHAEL P
IPC: A61B17/12
Filed: 2001-12-26
Abstract: The present invention involves a magnetic embolization apparatus for embolizing an aneurysm of a blood vessel. The apparatus includes a coiled element adapted for insertion within an aneurysm of a blood vessel, the coil ed element shaped to be retained within the aneurysm, and one or more permanent  magnetic segments carried by the coiled element to internally induce a magnetic field from within the aneurysm to control a magnetic field controllable embolic to embolize the aneurysm.
Patent CA-2439167-A1 (CA)
Inventor: REISINGER WERNER
IPC: G01N22/02
Filed: 2002-02-20
Abstract: The invention relates to a method and to a device for testing electronic circuits or the parts thereof on printed circuits. The inventive method comprises the following steps: (a) detecting the radiation that is emitted by the surface of the printed circuit, (b) converting the detected radiation to data that represent a surface structure and/or depth structure of the printed circuit, (c) comparing the data of the surface structure and/or the depth structure with stored data of a desired state of the surface structure and/or depth structure, and (d) determining any deviations between the data of the detected surface structure and/or depth structure and the data of the desired state of the surface structure and/or depth structure.
Patent CA-2439219-A1 (CA)
Inventor: INZE DIRK
IPC: C07K14/415
Filed: 2002-02-22
Abstract: The present invention relates to a method to isolate plant genes or gene fragments that are regulated by stress, preferably oxidative stress in plants.  The method comprises isolation of plant material, adaptation of the plant material to stress, differential expression of genes or gene fragments in adapted and non-adapted plant material, and isolation of the differential expressed genes or gene fragments. The invention further relates to the genes or gene fragments that can be obtained by this method and to the use of these genes or gene fragments to modulate plant stress tolerance.
Patent CA-2439471-A1 (CA)
Title: Promoteurs de croissance et/ou de differenciation de cellules souches heematopoietiques et/ou progenitrices hematopoietiques
Inventor: HARUYAMA MUNETADA
IPC: A61K38/19
Filed: 2002-12-27
Abstract: L'invention vise à créer des agents favorisant la prolifération et/ou la différenciation de cellules souches hématopoïétiques et/ou de précurseurs hématopoïétiques, utiles comme remèdes à des maladies induites par la prolifération et/ou la différenciation insuffisantes de cellules souches hématopoïétiques et/ou de précurseurs hématopoïétiques, en particulier des maladies associées à une diminution diffuse des cellules hématopoïétiques et/ou à une hypofonction hématopoïétique. A cet effet, les agents selon l'invention, favorisant la prolifération et/ou la différenciation de cellules souches hématopoïétiques et/ou de précurseurs hématopoïétiques, contiennent de la cofiline comme principe actif.
Patent CA-2441765-A1 (CA)
Title: Ultrasonic scalpel
Inventor: JEWETT WARREN R
IPC: A61B18/00
Filed: 2002-03-08
Abstract: A light, self-contained, hand held, ultrasonic surgical scalpel having a housing, an ultrasonic power source within the housing, to which ultrasonic vibrations are provided to a blade to which result in cutting features by lateral motion as well as by reciprocating motion imparted to the blades with said cutting action being adjustable.
Patent CA-2442559-A1 (CA)
Title: A method and system for managing configuration changes in a data processing system
Inventor: PICHETTI LUIGI
IPC: G06F21/00
Filed: 2002-03-05
Abstract: A method of managing configuration changes in a data processing system, particularly a network wherein software products (250) must be distributed t o client workstations. The method provides the definition of reference models (220e-220d) arranged in a tree (215); each reference model includes configuration elements (such as software products and/or hardware features a nd their desired target status) for the corresponding client workstations (subscribers). A target configuration (230) of the client workstations associated with each reference model is determined by inheriting the configuration elements of the parent reference models. A list of actions (24 5) to be carried out on each client workstation for reaching the corresponding target configuration is determined by comparing the target configuration wit h a current configuration of the client workstation stored in a corresponding inventory (245).